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INTRODUCTION 
Vascularized organ transplants can be rejected by either humoral or cell 
mediated mechanisms that are not mutually exclusive. This is not unex-
pected given the relation of both arms of the immune system. Cell mediated 
rejection in naive recipients of allografts is a first set immune event, generally 
requiring days to development of cellular rejection. Yet, donor specific anti-
bodies can be detected in allografts which are undergoing first set rejection. 
On the other hand, proliferative and cytotoxic donor specific T cell responses 
can be detected in vitro in animals which have been presensitized to donor 
antigens. Isolated reports of accelerated cell mediated rejection exist in sen-
sitized recipients, (Eichwald et a11985) but overall this is uncommon, and the 
focus of this chapter will be to discuss the role of antibodies in accelerated liver 
transplant rejection. 
CHARACTERIZATION OF ANTIBODIES INVOLVED IN REJECTION 
The phenomenon of hyperacute rejection was first recognized as being 
related to preformed antibodies in kidney allografts transplanted in ABO 
incompatible combinations. These findings were also noted in recipients 
bearing lymphocytotoxic antibodies, as a result of pregnancy, previous blood 
transfusions or failed grafts. The importance of avoiding transplantation of 
kidney allografts into recipients bearing preformed antidonor antibodies was 
noted in many early reports describing hyperacute rejection (Starzl 1964, 
Terasaki et all965, Kissmeyer-Nielsen et al 1966, Williams et all968, Starzl 
et al 1970). The impact of preformed antibodies in other vascularized organ 
allografts is variable, with the heart being susceptible to antibody rejection, 
(Rose 1991) while the liver is less vulnerable. (Starzl 1969, 1974, 1987, 
Garnier 1965, 1970, Cordier 1966, Caine 1967a, b, 1969, 1970a, Peacock 
1967, Lempinen 1971, Mazzoni 1971, Iwatsuki 1981, 1984, Houssin 1985, 
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1987, Knechtle 1987a, b, Gugenheim 1988a, 
b, Demetris 1988, 1989, Davies 1989, 
Suminoto 1991, Furuya in press). 
In xenotransplantation, preformed antibod-
ies occur narurally, without prior exposure to 
antigens from other species of animals. These 
antibodies are capable of mediating a brisk hy-
peracute rejection (Perper 1966a, b, Calne 1970b, 
Giles 1970). It is thought that these naturally 
occurring antibodies are the results of exposure 
to common environmental antigens (Marino 
1990, First 1992). These antibodies react with 
glycolipids and glycoproteins on the cell surface 
of the xenograft. 
The class of immunoglobulins involved 
in hyperacute rejection depends on the anti-
genic determinants which the antibodies rec-
ognize. Lymphocytotoxic antibodies to MHC 
determinants, as a result of prior transfusion 
or failed allografts, are often of the IgG class. 
Both xenoantibodies and, to a great extent, 
ABO isoagglutinins are of the IgM class, but 
high titers ofIgG can be induced by sensiti-
zation. The titer of preformed xenoantibodies 
and ease of inducing xenoantibodies was pro-
posed to be able to provide an assessment of 
phylogenic diversity (land steiner 1962), hence 
the designation of discordant and concordant 
combinations (Caine 1970b). 
In the discordant xenotransplant combi-
nation, IgM and IgG can be shown to exist in 
high titers, such as in the guinea pig-to-rat 
combination (Gambiez 1990), the pig-to-
Rhesus monkey combination (Fischel 1990) 
and the pig-to-dog combination (Giles 1970, 
Makowka 1987). In concordant xenotransplant 
combinations IgM may exist, usually in low 
titers, such as in the hamster-to-rat combina-
tion (Valdivia 1987a), the fox-to-dog combi-
nation (Brendel 1977), and baboon-to-rhesus 
monkey combination (Marquet 1978). In both 
combinations, sensitization following transplan-
tation generally results in an abrupt rise in the 
IgM titer followed shortly by an increase in the 
IgG titer. In a few models, other classes of 
immunoglobulins besides IgG and IgM, can 
cause hyperacute rejection. In some of our pre-
vious experimental studies, IgA and IgG were 
able to initiate hyperacute rejection in a kidney 
transplant model (Marino 1990, 1991). 
PATHOPHYSIOLOGY OF ANTIBODY 
MEDIATED REJECTION 
Independent of the nature of immuno-
globulin class of preformed antibody involved 
in triggering antibody mediated rejection, 
the pathophysiology of the acute inflamma-
tory response is similar. Preformed antibodies 
trigger rejection by their deposition on the 
endothelium of the vascularized graft. These 
antibodies in turn activate complement, which 
in turn activates a characteristic cascade of 
inflammatory, nonspecific mediators, such as 
recruitment of polymorphonuclear leukocytes, 
platelet adhesion and degranulation, followed 
by intravascular thrombosis (Starzl 1964, 
Kissmeyer-Nielsen 1966, Williams 1968, 
Giles 1970) (Figs. 1 and 2). 
Complement activation can occur via the 
classical and alternative complemenr path-
ways. In the classical pathway, the C1q com-
ponent of C1 is activated following binding 
to the Fc region of IgM and IgG. This in rum 
results in C 1 rand Cis activation and tbe 
generation of the C1qrs protease complex, in 
turn leading to C4 and C2 cleavage, produc-
ing the C3 convertase, C4b2a complex. C3 is 
then cleaved to produce the biologically ac-
tive components, C3a and C3b. In the alter-
native pathway, complemenr can be activated 
via IgA, IgE and other nonimmunologic fac-
tors such as polysaccharides and bacteria. 
Activation of C3 occurs via nonspecific cleav-
age to generate C3b. 
The common pathway of complement 
activation is via the C5 cleavage which gen-
erates C5b which in turn leads to the assem-
bly of the C5b-C9 membrane attack com-
plex. This membrane attack complex binds 
to the cell surface resulting in a porous mem-
brane which is susceptible to osmotic pressure 
leading to either cell damage or cell death. 
Cell damage also occurs by activation of 
other inflammatory pathways. Reactive oxy-
gen metabolites, prostaglandins and cytokines 
can be generated by the degradation products 
of complement activation (Forbes 1982). Poly-
morphonuclear leukocytes and macrophages 
are attracted to the site of inflammation via 
the C5a fragment, which results in the release 
of lysosomal enzymes and resultant cell dam-
age (Forbes 1984). C3b also enhances adhe-
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sion of these cells to damage cells. C3b also 
promotes binding of platelets which may lead 
to degranulation and release of vasoactive 
substances, such as serotonin and histamine, 
both increasing vascular permeability. 
Thrombosis of the microvasculature is 
enhanced by the loss of membrane associated 
heparin sulfate, from the endothelial cell. The 
release of tissue factors from injured cells also 
promotes thrombosis. 
The importance of complement in the 
pathophysiology of antibody mediated rejec-
tion is shown in studies in which comple-
ment is depleted. Cobra venom inactivates 
the C3 component, resulting in paralysis of 
the complement system (Kemp 1982, Adachi 
1987, Johnston 1992). Hasan and coworkers 
have been able to obtain long-term survival 
Fig. 1. Electron photomicrograph ofaxenografted 
kidney (pig-to-rabbit) tissue sample obtained 15 
minutes after reperfusion. In the peritubular capil-
larya monocyte, erythrocytes and platelets (show-
ing some adherence to the endothelium) can be 
observed. The interstitium is edematous (x4600). 
(Reprinted from: Histopathological, immunofluo-
rescent, and electron-microscopic features of hy-
peracute rejection in discordant renal xeno-
transplantation, by Marino JR et at in Xeno-
transplantation, Cooper OKC Kemp E, Reemtsma 
K, and White OJG eds., Springer-Verlag, Berlin, 
Chapter 12, Fig. 12.6, p.214, 1991). 
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of xenografts during treatment with cobra 
venom factor (Hasan 1992). 
SUSCEPTIBILITY OF THE LIVER 
TO ANTIBODY MEDICATED REJECTION 
Transplanted livers have been reported to 
be relatively resistant to both cell mediated 
and antibody mediated rejection (StarzI1969, 
1974, 1987, Garnier 1965, 1970, Cordier 
1966, Caine 1967a, b, 1969, 1970a, Peacock 
1967, Lempinen 1971, Mazzoni 1971, 
Iwatsuki 1981, 1984, Houssin 1985, 1986, 
Gordon 1986a, Orosz 1986, Gubernatis 1987, 
Knechtle 1987a,b, Gugenheim 1988a,b, 
Demetris 1988, 1989, Davies 1989, Suminoto 
1991, Furuya, in press). Liver allografts were 
shown to have prolonged survival when com-
pared to organs and tissues, when immuno-
Fig. 2. Electron photomicrograph ofaxenografted 
kidney (pig-to-rabbit) tissue sample obtained 720 
minutes after reperfusion. The urinary space of the 
glomerulus is completely occupied by ce/l debris, 
and the epithelial cells of the Bowman's capsule 
are dramatica/ly damaged (x4600). (Reprinted from: 
Histopathological, immunofluorescent, and elec-
tron-microscopic features of hyperacute rejection 
in discordant renal xenotransplantation, by Marino 
IR et ai, in Xenotransplantation, Cooper OKC 
Kemp E, Reemtsma K, and White OJG eds., Springer-
Verlag, Berlin, Chapter 12, Fig. 72.75, p.223, 7997). 
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suppression is not given. In fact, several groups 
have demonstrated spontaneous liver allograft 
survival in the porcine model, without im-
munosuppression (Caine 1967a, b, Peacock 
1967, Lempinen 1971, Mazzoni 1971). 
A number of observations on the effect of 
the presensi tized state on liver transplant 
survival suggests that the liver is less suscep-
tible to antibody mediated rejection. Starzl 
and coworkers have noted resistance of hu-
man liver allografts to humoral rejection 
(Starzl 1974, Iwatsuki 1981,1984). This re-
sistance is sufficient to allow transplantation 
under conditions which would be unaccept-
able for kidneys. It has been evident that 
hyperacute rejection of the liver does not com-
monly occur with lymphocytotoxic presen-
sitized states, while occurring more frequently 
with ABO-incompatible liver transplants. 
While a penalty accrues to those patients 
receiving ABO-incompatible liver allografts, 
there were a surprisingly large number of 
such grafts that were successful (Starzl 1974, 
1987, I watsuki 1981, ] 984, Gordon 1986a, 
Demetris 1988, 1989, 1992, Rego 1987, 
Gugenheim 1989, 1990, Fischel 1989). The 
pathology of the ABO-mismatched livers 
which failed revealed evidence of humoral 
rejection, with hemorrhagic necrosis and 
intra parenchymal coagulation (Demetris 
1988, 1989). The long-term complication of 
ABO-incompatibility may also manifest with 
biliary tract complications (Starzl 1987, 
Demetris 1989, Sanchez-UrdazpaI1991). This 
pattern of rejection is rarely seen in liver 
allografts in which a positive lymphocytotoxic 
crossmatch occurs. As would be predicted, 
the pattern of xenoantibody rejection of the 
liver is much more similar to that of ABO-
incompatibility than for MHC specific sensi-
tization. In animals receiving a discordant 
liver transplant, IgM and IgG deposition on 
the vascular endothelium and sinusoids is also 
accompanied by complement activation. Vas-
cular thrombosis due to platelet aggregation 
leads to hemorrhagic necrosis, with little or 
no cellular infiltrates. 
The relative resistance of the liver al-
lograft to antibody mediated rejection ap-
pears to confer some protection systemically, 
presumably by neutralizing or reducing the 
titer of lymphocytotoxic antibodies. One of 
the possible explanations for this unique ca-
pacity of the liver to withstand antibody at-
tack is the observation that the liver is a 
source of soluble MHC Class I antigens (Davies 
1989, Suminoto 1991). These soluble MHC 
antigens may neutralize the circulating anti-
donor antibody (Houssin 1985, 1986, Orosz 
1986, Gugenheim 1988a, b). In addition, the 
liver serves as a rich reticuloendothelial or-
gan, removing circulating immune complexes 
by actions of the Kupffer cell which lines a 
nonendothelial vascular network which is less 
susceptible to vasoactive substances than end-
organ vessels such as seen with the heart and 
kidney. 
Extracorporeal donor-specific liver hemo-
perfusion can reduce the level of cytotoxic 
antibodies in hypersensitized rats (Orosz 1986, 
Gugenheim 1985,1988, Kamada 1988). This 
finding was the premise to urilize the liver 
allograft to protect the subsequent kidney 
allograft in patients with preformed donor-
specific antibodies (Fung 1988, Flye 1990). 
The lymphocytotoxic crossmatch in patients 
with preformed antibodies will often convert 
ftom positive to negative following liver trans-
plantation. When this occurs, placement of a 
kidney allograft from the same donor will 
often result in prevention of hyperacute rejec-
tion of the kidney (Fung 1988, Flye 1990). It 
should be noted that this protection is not 
universal, and cases of rejection of the kidney 
following liver transplantation have been re-
ported (Starzl 1989). 
In spite of the unique immunologic prop-
erties of the liver, reports of accelerated rejec-
tion of the liver have been published (Hanto 
1987, Bird 1989, Starzl 1989, Karuppan 
1991). Knechtle and coworkers noted that 
the resistance of liver allografts to rejection 
could be overridden by presensitization with 
skin grafts (Knechtle 1987a,b). In 9 of 10 
presensitized rat recipients, hyperacute rejec-
tion was noted, and immunofluorescence could 
detect IgG and complement in the sinusoids 
and perivascular tissues. Murase and cowork-
ers also noted antibody mediated rejection in 
an arterialized rat liver transplant model if 
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the recipients had received at least four skin 
grafts from the donor, and if the transplant 
was performed within nine weeks (Furuya in 
press). In a porcine model of acceptance of 
liver allografts, the liver allograft could be 
induced to be uniformly rejected when the 
recipient pigs were presensitized, either by 
prior skin grafting or kidney transplantation 
(Caine 1969). In a primate srudy, Gubernatis 
and coworkers demonstrated that hyperacute 
or accelerated rejection of the liver could be 
observed (Gubernatis 1987). 
The first report of hemorrhagic necrosis 
following human liver transplantation was by 
Williams and Hume, more than 25 years ago 
(Hume 1969). In 1987, Hanto and coworkers 
published a case report of hyperacute rejec-
tion in a strongly positive T cell crossmatched 
recipient (Hanto 1987). The pattern of rejec-
tion in this patient was notable for a lack of 
antibody and complement in the sinusoids or 
portal vessels. The adverse effect of lympho-
cytotoxic antibodies in liver allograft survival 
in human liver transplantation may have been 
masked by the immunosuppression which has 
been utilized in most immunosuppressive 
regimens. In contrast to the early reports on 
the relative lack of effect of a positive 
crossmatch on liver allograft survival (lwatsuki 
1981, 1984), Takaya and coworkers noted 
that there was an increased graft loss in these 
patients (Takaya 1992a). The principle dif-
ference in the two populations was the utili-
zation of high dose steroids in the former 
group, while low dose steroids (20 mg/day) 
were utilized in the latter group. In fact, 
when the steroid doses were increased in sub-
sequent positive crossmatch liver recipients, 
the incidence of graft loss decreased. 
TREATMENT OF THE 
PREFORMED ANTIBODY STATE 
Since 1956 a number of treatments have 
been proposed as methods to reduce preformed 
antibodies, or to minimize the damage which 
would be antibody mediated (Clark 1964, 1966, 
Gerwurz 1966, Rosenberg 1969, 1971a, b, Shons 
1970,1973, 1974a, b, Bier 1970, Moberg 1971, 
Hawkins 1971, Kux 1971, Merkel 1971, 
Baldamus 1973, Winn 1973, Kemp 1982,1976, 
1977, 1987a, b, Shapiro 1990a). These include: 
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antibody depletion (including specific and non-
specific antibody removal), interruption of the 
clotting cascade, and interruption of the comple-
ment cascade. 
Several antibody depletion techniques 
have been utilized in the past 30 years. The 
first report of thoracic duct drainage (TOO) 
was in 1964 (Franksson 1964, 1967, 1976). 
A number of series of patients treated with 
TOO in the pre-cyclosporine era, undergoing 
kidney transplantation, have been reported 
(Sonoda 1966, Murray 1968, Tilney 1968, 
1970, Archimbaud 1969, Martelli 1970, 
Sarles 1970, Estevam 1974, Walker 1977, 
Johnson 1977, Starzl 1979a, b, Koep 1980, 
Ono 1987, Ohshima 1981, 1987, 1988, 
1989c, d). In these series, it was noted that 
the level of lymphocytotoxic antibodies fell 
during the course of TOO. However, with 
the advent of cyclosporine, the cumbersome 
use of TOO has been largely abandoned. 
Plasmapheresis has also been utilized to 
lower preformed antibody levels. This tech-
nique has also been combined with cyclo-
phosphamide, an antiproliferative agent 
(Marino 1993), in highly sensitized patients 
receiving kidney transplants (Taube 1984a, 
b). Its use in the posttransplant period to re-
verse established antibody rejection has met with 
varying success (Cardella 1977, Naik 1979, Rifle 
1979, Kirubakaran 1981, Power 1981). The 
cost and variable efficacy ha~ also led to aban-
donment of this procedure. 
A relatively newly described method to 
lower antibody levels is the ability of the 
Staphylococcus aureuJ Protein A to bind to the 
Fc receptor ofIgG (Forsgren 1966). The ap-
plication of this principle to column tech-
nology has allowed Protein A to be bound 
covalently to cyanogen bromide activated 
Sepharose B, creating a solid phase immuno-
absorbant. It has been possible to deplete 
serum IgG levels by 75-90% with a single 
treatment (Shapiro 1990a). Few clinical trials 
have been performed both in Europe and in 
the United States, and the results have also 
been variable (Palmer 1987, 1989, Gjorstrup 
1988, Shapiro 1990b.) 
The use of antigen-specific antibody 
depletion has centered on the pre-perfusion of 
a donor vascularized organ prior to trans plan-
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tation. Reports by Starzl and coworkers with 
pre-perfusion of liver, kidneys and spleen by 
heterotopic ex vivo perfusion of the recipient, 
was shawn to immediately decrease the levels 
of preformed antibodies (Giles 1970). This 
allowed prolonged graft survival in situations 
which normally would lead to rejection. 
Other techniques to control the damage 
mediated by preformed antibodies have fo-
cused on abrogating the inflammatory me-
diator response (Makowka 1987), interrupt-
ing the clotting cascade (Giles 1970, 1971, 
Kux 1971, Moberg 1971,Kemp 1976, 1977, 
1982), or preventing complement activation 
(Moberg 1971, Kemp 1982, Adachi 1987, 
Johnston 1992, Hasan 1992). Unfortunately, 
none of these techniques have resulted in clini-
cal applications. Inhibition of soluble media-
tors with antiplatelet activating factors have 
provided encouraging laboratory results, es-
pecially if combined with prostaglandins, but 
generally at the expense of an hemorrhagic 
diathesis. Kux and coworkers described the 
use of a calcium chelatir>g agent, sodium ci-
trate, over 20 years ago (Kux 1971). Citrate 
theoretically functions by virtue of its 
anticoagulation ability, but also secondarily 
by inhibition of complement activation, which 
is also calcium dependent. In this model, 
citrate was perfused intra-arterially into the 
vascularized organ. Unfortunately, the doses 
of citrate which are required, soon led to 
ci trate intoxication. 
Prevention of complement activation is a 
strategy which is attractive for future devel-
opment. Cobra venom, which was described 
over 20 years ago for its ability to prevent 
complement activation, is also a potent anti-
coagulant. It has been effective in prolonging 
the hyperacute rejection of guinea pig hearts 
in a discordant xenograft model using rats as 
recipients (Johnston 1992). 
USE OF FK506 IN 
PRESENSITIZED STATES 
Nonspecific immunosuppression has been 
utilized to decrease the immune responsive-
ness in preformed antibody states. Many of 
these agents have required "cocktail" therapy, 
including agents which act on different limbs 
of the immune response (Murase 1993, in 
press). Cyclosporine has not been very effec-
tive in the xenograft models (Adachi 1987, 
Valdivia 1987b, Gambiez 1990). On the other 
hand, another T cell specific immunosup-
pressive agent, FK506, has some effect in 
xenograft models, in which the level of pre-
formed antibodies is low (Valdivia 1987a). 
FK506 is a newly described macrolide 
antibiotic, with potent suppression of both 
cell mediated and T cell dependent antibody 
responses (Kino 1987, Starzl 1991). 
The large experience accumulated in the 
last four years with the clinical use of FK506 
showed very encouraging results (StarzI1991) 
when compared with the other drugs pres-
ently used. However, limited information is 
available on the effect of FK506 on the hu-
moral response, both experimentally and clini-
cally. In 1988, Woo et al (Woo 1988), dem-
onstrated profound suppression of the 
production of splenic IgM-secreting plasma 
cells and antibody levels in rats immunized 
with sheep red blood cells. IgM-producing 
splenic plasma cells underwent a 93% reduc-
tion in the group of animals treated with 
FK506 in association with cyclosporine, and 
a 98% reduction in the group treated with 
FK506 alone. Inamura et al (Inamura 1988), 
that same year, and Takagishi et al (Takagishi 
1989), the following year, showed that when 
FK506 treatment was begun on the same day 
as type II collagen immunization, FK506 in-
hibited the development of arthritis and sup-
pressed and immunological response to type 
II collagen in rats. These findings, along with 
the fact that experimental arthritis can be 
induced in congenitally athymic nude rats by 
humoral mechanism alone (Takagishi 1985), 
can be explained as a resul t of the i nhibi tion 
of anticollagen antibody production by 
FK506. 
Our group has reported in the past 
(Iwatsuki 1981, 1984, Gordon 1986b) that 
one and two year liver graft survivals were not 
adversely affected by the Iymphocytotoxic an-
tibody and that a positive crossmatch was not 
a contraindication for liver transplantation. 
However, the fact that many of the crossmatch 
positive patients were highly sensitized and 
that specific alloimmunization of platelets to 
class I antigens is a major cause of bleeding 
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and platelet transfusion refractoriness in liver 
transplant candidates was documented shortly 
thereafter (Marino 1988). These facts, along 
with the knowledge that crossmatch-positive 
liver grafts have been lost for unclear reasons 
(Han to 1987, Bird 1989, Starzl 1989, 
Karuppan 1991) in different centers moti-
vated us to reanalyze the effect of antidonor 
lymphocytotoxic antibody upon graft survival. 
Takaya et al demonstrated, for the first time 
and in the largest patient series available, that 
anti donor lymphocytotoxic antibody (posi-
tive crossmatch) adversely affects the survival 
of primary liver transplantation during the 
first 12 months after surgery (Fig. 3) (Takaya 
1991, 1992a). These studies showed an in-
creased incidence of graft failure from rejec-
tion, and of vascular and biliary complica-
tions in this population. The adverse impact 
of using positive cytotoxic crossmatch donors 
was evident both under cyclosporine or FK506 
as primary immunosuppressant (Takaya 1991, 
1992a). There was no difference in the one-
GRAFT SURVIVAL(%) 
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year graft survival between 25 posi tive 
crossmatch patients in the FK506 era (56%), 
when compared to 22 positive cross match 
patients in the cyclosporine era (59%) (Takaya 
1991, 1992a). Similar results in a series of 
liver transplant patients have been also re-
ported by Karuppan et al in Sweden 
(Karuppan 1991). None of the grafts in this 
Swedish series were hyperacutely rejected, and 
graft survival was significantly lower in the 
group of patients that had cytotoxic antibod-
ies reactive with donor splenic T and/or B 
cells. Nakamura et al (Nakamura 1991) con-
ducted a clinicopathologic analysis of 26 liver 
transplant recipients harboring preformed 
dithiothreitol (DTT) resistant (lwaki 1988) 
lymphocytotoxic antibodies. These 26 patients 
were identified among adult patients who 
received primary liver allografts under FK506 
immunosuppression at the University of Pitts-
burgh. Similar to the smaller Swedish series, 
none of the grafts of this Pittsburgh series 
underwent "hyperacute" rejection. On the 
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60 _. 
p<O.005 
40 _. 
20 ................................ ,--------,. 
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Fig. 3. The actuarial graft survival rates in 25 adult liver transplant positive-crossmatch patients and 50 
negative·crossmatch patients (Reprinted from: The adverse impact on liver transplantation of using 
positive cytotoxic crossmatch donors, by Takaya S. et al. in Transplantation 53(2}:p.40 i, Fig. 7, 1992). 
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other hand, when compared to cross match 
negative control patients, the crossmatch 
positive recipients had prolonged early graft 
dysfunction, a significantly larger number of 
clinically indicated biopsies, and of biopsy 
proven early acute cellular rejection within 
the first 10 post transplant days. There was 
also a higher incidence of graft failure within 
the first two months. Furthermore, pathologic 
specimens from these positive crossmatch 
patients showed early platelet margination in 
central veins and sinusoids, neutrophilic por-
tal venulitis followed by cholangiolar prolif-
eration, acute cholangiolitis, centrilobular 
hepatocyte swelling (mimicking "preserva-
tion" injury), relapsing episodes of acute cel-
lular rejection and endothelial activation of 
arteries with medial changes. A significant 
clinical difference in the course of these pa-
tients is represented by the fact that the 
centrilobular hepatocyte swelling mimicking 
a "preservation" injury often do not resolve 
(as generally happens in the "true" preserva-
tion injury) but rather tend to persist or worsen 
in the posttransplant weeks. All these 
pathologic events indicated that transplant 
recipients harboring preformed DTT -resis-
tant lymphocytotoxic antibodies have a worse 
early posttransplantation graft function and 
survival, even though in these FK506-treated 
recipients hyperacute or accelerated rejection 
was not seen. These clinicopathologic results 
were actually very similar to the experimental 
observations by Houssin et al (Houssin 1985, 
1986), and Furuya et al (Furuya in press). In 
fact, the seven (27%) failed allografts from 
crossmatch positive patients in the Pittsburgh 
series showed significant changes in the arter-
ies and in the peri biliary vascular plexus 
(Nakamura 1991). The medium-sized muscu-
lar arteries presented changes suggestive of arte-
rial spasm (Nakamura 1991), resembling the 
changes observed in sensitized rats (Furuya in 
press). Also, medial thickening was common 
and an analysis of the arterial wall thickness/ 
diameter ratio resulted in a significant differ-
ence between the crossmatch positive patients 
and the controls. Immunofluorescence revealed 
venous and sinusoidal IgG, Clq, and C3 depo-
sition only in biopsies performed 6-24 hours 
after liver reperfusion (Iwaki 1988). No signifi-
cant immune deposits were detectable later in 
biopsy specimens. This was the only important 
dissimilarity between the clinical (Nakamura 
1991) and the experimental (Furuya in press) 
pathologic findings. 
Differing from renal grafts, where humoral 
rejection does not respond to immunosuppres-
sion, there is clinical evidence that sensitized 
liver allograft recipients may resist an antibody-
mediated rejection if an FK506 based immune 
suppression regimen is used (Woodle 1991, 
Takaya 1992b). Woodle et al (Woodle 1991) 
reported a case of biopsy proven liver humoral 
rejection, where an ABO-incompatible donor 
organ was used (A to 0), that promptly resolved 
after switching the patient to FK506 im-
munosuppression. Initial post transplant liver 
biopsies showed several features of humoral 
rejection, including arteriolar hyaline necro-
sis, disrupted endothelium, intraluminal fi-
brin deposition, and IgM and complement 
endothelial deposition. All these findings re-
gressed four days after FK506 treatment was 
started and disappeared in eight days. Even 
though plasmapheresis and OKT3 were used 
perioperatively the clinicopathologic picture 
dramatically improved only when FKS06 
therapy was initiated, unequivocally supporting 
the use of this drug in a similar condition. 
More recently, Takaya et al (Takaya 
1992b) reported their experience in posi tive 
cytotoxic crossmatch liver transplant patients 
using FKS06 in conjunction with high dose 
steroids and prostaglandin EJ (PGE J) 
(Quagliata 1972, Mundy 1980, Rappaport 
1982, Strom 1983, Shaw 1985, Makowka 
1987, Starz11993, Marino 1993). Using this 
immunosuppressive strategy it was possible 
to convert the prognosis of recipients harbor-
ing preformed cytotoxic antibodies to essen-
tially the same as that of the conventionally 
treated crossmatch negative recipients. In fact, 
the six-month graft survival rate in the posi-
tive crossmatch patients treated with low dose 
steroids was only 60.7%, while the six-month 
graft survival rate in the group treated with 
high dose steroids and PGE[ was 92.9% 
(P=O.03). This Pittsburgh study, along with 
the experience reported by Woodle et al 
(Woodle 1991) indicates that it is possible 
under FK506 treatment to transplant a liver 
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into a sensitized recipient with a reasonable 
expectation of avoiding accelerated or hyper-
acute rejection. However, long-term results 
are needed before it can be concluded that the 
strengthened immuno- suppression can ame-
liorate the effects of preformed antibodies to 
the point that this should not be considered 
an issue. A longer clinicopathologic follow-
up should clarify if the better short-term re-
sults are not subsequently diminished by bi-
liary or vascular complications like biliary 
sludge, bile duct necrosis or small bile duct 
loss. These could appear later and neverthe-
less be the result of an initial antibody medi-
ated damage. If the long-term follow-up does 
not show an increased incidence of any of 
these complications a positive crossmatch or 
an ABO-incompatibility would not be con-
sidered an absolute contraindication to liver 
transplantation in the FK506 era. Especially 
considering the observation of" mutual natu-
ral immunosuppression" that is established 
between the donor and the recipient by the 
donor-recipient cell traffic starting immedi-
ately after reperfusion (Iwaki 1991). Recently, 
Starzl and Demetris (Starzl submitted) stated, 
on the basis of the Pittsburgh investigations 
on mixed allogeneic microchimerism that "if 
the initial storm can be weathered, as has 
been increasingly possible with modern im-
munosuppression, the anticipated typing ef-
fect dwindles". Most probably FK506, along 
with "old" immunosuppressive drugs (ste-
roids, PGE], cyclophosphamide) (Marino 
1993, Starzl 1993) and possible manipula-
tion of immune cells effecting the micro-
chimeric state (Monaco 1970, Caridis 1973, 
Slavin 1977, Thomas 1983, Ildstad 1985, 
Barber 1991, Starzl submitted) will allow the 
antibody barrier in allo- and 
xenotransplantations to be routinely overcome. 
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